Australian Partnership (for) Preparedness Research On InfectiouS (disease) Emergencies (APPRISE)
Funder
National Health and Medical Research Council
Funding Amount
$4,996,416.00
Summary
We have assembled national experts in clinical, laboratory and public health research to ensure Australia is equipped for a coordinated, effective and evidence based response to infectious diseases. This multidisciplinary team will create and share new knowledge to detect, prevent and manage emerging infection threats. We will train a robust cross-sectoral work force and develop sustainable research capacity integrated within the health system to ensure national and regional health security.
Diseases caused by the pneumococcus represent the largest cause of vaccine preventable death in the world today, mainly pneumonia and meningitis. In 2011, 16 developing countries will introduce pneumococcal conjugate vaccines, none in east Asia. Lack of research has been a major barrier to their use in the region. We have established an international centre of excellence in the field and we seek support to extend the capacity of this group and to transfer the technology to Vietnam.
Centre Of Research Excellence On Sitting Time And Chronic Disease Prevention – Mechanisms, Measurement And Interventions
Funder
National Health and Medical Research Council
Funding Amount
$2,657,874.00
Summary
Australian research has identified serious health consequences arising from the 7 to 10 hours of daily sitting that most people do, especially in relation to ‘diseases of inactivity’ – type 2 diabetes, coronary heart disease and breast and colon cancer – that are an unwelcome burden on individuals, families and health systems. This new research examines the practical feasibility and the preventive-health benefits of changing children’s and adults’ sitting time in schools, workplaces and the home ....Australian research has identified serious health consequences arising from the 7 to 10 hours of daily sitting that most people do, especially in relation to ‘diseases of inactivity’ – type 2 diabetes, coronary heart disease and breast and colon cancer – that are an unwelcome burden on individuals, families and health systems. This new research examines the practical feasibility and the preventive-health benefits of changing children’s and adults’ sitting time in schools, workplaces and the home environment.Read moreRead less
CENTRE OF RESEARCH EXCELLENCE TO REDUCE INEQUALITY IN HEART DISEASE
Funder
National Health and Medical Research Council
Funding Amount
$2,607,253.00
Summary
There is increasing recognition of a societal responsibility to provide effective and sustainable health care to the entire population and not just to selected parts. Indigenous and regional Australians are most affected by Australia's biggest killer - heart disease. In response, the CRE to Reduce Inequality in Heart Disease, is a national collaboration of researchers from a range of health disciplines. Together they aim to address this problem by developing sustainable and cost-effective health ....There is increasing recognition of a societal responsibility to provide effective and sustainable health care to the entire population and not just to selected parts. Indigenous and regional Australians are most affected by Australia's biggest killer - heart disease. In response, the CRE to Reduce Inequality in Heart Disease, is a national collaboration of researchers from a range of health disciplines. Together they aim to address this problem by developing sustainable and cost-effective health care services.Read moreRead less
Centre For Research Excellence In Malaria Elimination
Funder
National Health and Medical Research Council
Funding Amount
$2,470,291.00
Summary
The CRE will work to accelerate progress towards malaria elimination in our region, through Surveillance, to develop better ways to monitor malaria transmission and discover who is infected, and to track movement of malaria parasites and spread of drug resistance. Diagnosis, to develop and test new, more sensitive ways of detecting malaria. Treatment, to fast track development of new antimalarials, and improve access to ensure all infected people get highly effective drugs.